Directory
Antonia Salud Salvia

Antonia Salud Salvia

Degree: PhD


masalud.lleida.ics(ELIMINAR)@gencat.cat

Groups

Publications

  • Porcel, JM; Sorolla, A; Parisi, E; Bielsa, S; Salud, A; Sorolla, MA

    Cell-free DNA Concentration and Pattern Fragmentation in Pleural Fluid and Plasma to Detect Malignant Effusions.

    Annals of the American Thoracic Society 19 854-856. .

    [doi:10.1513/AnnalsATS.202107-810RL]

  • Benavides, M; Gómez-España, A; García-Alfonso, P; González, CG; Viéitez, JM; Rivera, F; Safont, MJ; Abad, A; Sastre, J; Valladares-Ayerbes, M; Carrato, A; González-Flores, E; Robles, L; Salud, A; Alonso-Orduña, V; Montagut, C; Asensio, E; Díaz-Rubio, E; Aranda, E

    Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

    EJSO 48 1123-1132. .

    [doi:10.1016/j.ejso.2021.11.122]

  • Elez, Elena; Gómez-España MA; Gravalos, Cristina; Garcia-Alfonso, Pilar; Ortiz-Morales MJ; Losa, Ferran; Díaz IA; Graña B; Toledano-Fonseca, Marta; Valladares-Ayerbes, Manuel; Polo, Eduardo; Salgado, Mercedes; Martinez de Castro, Eva; Safont MJ; Salud, Antonieta; Ruiz-Casado, Ana; Tabernero, Josep; Riesco MDC; Rodriguez-Ariza, Antonio; Aranda, Enrique

    Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial.

    BRITISH JOURNAL OF CANCER 126 874-880. .

    [doi:10.1038/s41416-021-01638-w]

  • Marques, M; Sorolla, MA; Urdanibia, I; Parisi, E; Hidalgo, I; Morales, S; Salud, A; Sorolla, A

    Are Transcription Factors Plausible Oncotargets for Triple Negative Breast Cancers?

    Cancers 14 -. .

    [doi:10.3390/cancers14051101]

  • Sorolla, MA; Hidalgo, I; Sorolla, A; Montal, R; Pallise, O; Salud, A; Parisi, E

    Microenvironmental Reactive Oxygen Species in Colorectal Cancer: Involved Processes and Therapeutic Opportunities

    Cancers 13 -. .

    [doi:10.3390/cancers13205037]

  • Astorga, BG; Ballabrera, FS; Aguilar, EA; Fernandez, EE; Garcia-Alfonso, P; Flores, EG; Garcia, RV; Montes, AF; Munoz, AML; Salvia, AS

    Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept

    CLINICAL & TRANSLATIONAL ONCOLOGY 23 1520-1528. .

    [doi:10.1007/s12094-021-02568-y]

  • Valladares-Ayerbes, M; Fonseca, MT; de Prado, JV; Inga-Saavedra, E; Gil, S; Suarez, BG; Garcia-Paredes, B; Salud, A; Herrero, FR; Fernandez, MS; Garcia-Alfonso, P; Lopez-Lopez, R; Monteagudo, RF; Sastre, J; Diaz-Rubio, E; Aranda, E

    Circulating RNA detection, circulating tumor cells count, and molecular tumor profiling in a cohort of untreated metastatic colorectal cancer: A prospective multicenter ancillary study to the randomized VISNU trials

    ANNALS OF ONCOLOGY 32 131-132. .

    [doi:10.1016/j.annonc.2021.05.154]

  • Sorolla MA; Sorolla A; Parisi E; Salud A; Porcel JM

    Diving into the Pleural Fluid: Liquid Biopsy for Metastatic Malignant Pleural Effusions.

    Cancers 13 -. .

    [doi:10.3390/cancers13112798]

  • Porcel JM; Murata P; Porcel L; Bielsa S; Pardina M; Salud A

    Prevalence, clinical characteristics, and outcome of pleural effusions in ovarian cancer.

    Pleura and Peritoneum 6 75-81. .

    [doi:10.1515/pp-2020-0152]

  • Vidal, J; Casadevall, D; Bellosillo, B; Pericay, C; Garcia-Carbonero, R; Losa, F; Layos, L; Alonso, V; Capdevila, J; Gallego, J; Vera, R; Salud, A; Martin-Richard, M; Nogue, M; Cillan, E; Maurel, J; Faull, I; Raymond, V; Fernandez-Martos, C; Montagut, C

    Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD1402 Trial

    CLINICAL CANCER RESEARCH 27 2890-2898. .

    [doi:10.1158/1078-0432.CCR-20-4769]

  • Sastre, J; Garcia-Alfonso, P; Vieitez, JM; Cano, MT; Rivera, F; Reina-Zoilo, JJ; Salud-Salvia, A; Quintero, G; Robles-Diaz, L; Safont, MJ; La Casta, A; Gil, S; Polo, E; Asensio-Martinez, E; Garcia-Paredes, B; Lopez, RL; Guillot, M; Valladares-Ayerbes, M; Aranda, E; Diaz-Rubio, E

    Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and < 3 baseline circulating tumour cells: the randomised phase II VISNU-2 study

    ESMO Open 6 -. .

    [doi:10.1016/j.esmoop.2021.100062]

  • Morales Murillo, Serafin; Gasol Cudos, Ariadna; Veas Rodriguez, Joel; Canosa Morales, Carles; Melé Olivé, Jordi; Vilardell Villellas, Felip; Sanchez Guzman, Douglas Rene; Iglesias Martínez, Edelmiro; Salud Salvia, Antonieta

    Selection of neoadjuvant treatment based on the 21-GENE test results in luminal breast cancer

    BREAST 56 35-41. .

    [doi:10.1016/j.breast.2021.01.001]

Projects

  • Decodificación de la metástasis del cáncer colorrectal desentrañando el señalosoma de PLA2G12A
  • Ajuts per a la contractació de personal investigador novell (FI)
  • Predicción de micrometástasis en pacientes con cáncer de colon localizado de alto riesgo
  • Dimerizaciones de HER2 como elemento de decición en la terapia dirigida anti-HER2 frente al cáncer de mama
  • UTILITAT PRONOSTICA DELS PERFILS D'EXPRESSIO PROTEICA EN PACIENTS AMB TUMOR RESIDUAL VIABLE (>1.0 CM) DESPRES DE LA QUIMIOTERAPIA NEOADJUVANT EN CANCER DE MAMA
  • Cáncer de mama: utilidad pronóstica de los Perfiles de Expresión Proteica en pacientes con tumor residual viable (>1.0 cm) tras quimioterapia neoadyuvante